ERNAGeneral
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
Ernexa Therapeutics has launched its CEO Corner platform to provide insights into the company's mission and scientific strategy. The inaugural video features CEO Sanjeev Luther discussing the company's commitment to developing innovative cell therapies for advanced cancer and autoimmune diseases. The platform aims to enhance communication with stakeholders and emphasize the importance of accessibility and affordability in treatment.
Read more →ERNAPhases
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Ernexa Therapeutics is advancing its lead oncology candidate, ERNA-101, with a planned IND submission in Q3 2026 and a first-in-human study expected in Q4 2026. The therapy aims to treat immunologically cold tumors, showing promising preclinical results. The company has completed key manufacturing and regulatory milestones, positioning itself for clinical-stage development.
Read more →ERNAGeneral
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Ernexa Therapeutics highlighted the unmet needs in ovarian cancer during a Virtual Investor KOL Connect segment featuring Dr. Ira Winer. The discussion focused on the limitations of current treatments and the potential of ERNA-101, which aims to activate immune responses in the tumor microenvironment. The engineered cell therapy may offer scalable solutions that improve accessibility for patients facing difficult-to-treat cancers.
Read more →ERNAPhases
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Ernexa Therapeutics has made significant strides in the development of its lead candidate, ERNA-101, by completing critical manufacturing milestones and transitioning to GMP manufacturing. The company is on track for an Investigational New Drug (IND) submission in Q3 2026, which will pave the way for its first-in-human clinical study. These advancements reflect Ernexa's commitment to addressing unmet medical needs in cancer and autoimmune diseases.
Read more →ERNAConferences/Events
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
Ernexa Therapeutics has released a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, who discusses the challenges in treating ovarian cancer and the potential of ERNA-101. The segment highlights the limitations of current therapies and elevates Ernexa's innovative approach with preclinical data showing successful tumor eradication. Dr. Ratner emphasizes the advantages of the company's engineered allogeneic iMSC platform, which aims to enhance accessibility and efficiency in treatment. This development underscores Ernexa's commitment to addressing significant unmet needs in the cancer treatment landscape.
Read more →ERNAConferences/Events
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
Ernexa Therapeutics has released a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, discussing the challenges in ovarian cancer treatment and the potential of their lead candidate, ERNA-101. The segment emphasizes the need for more effective therapies and outlines how ERNA-101 could enhance patient outcomes. Additionally, the company will participate in a Virtual Investor Closing Bell event on May 13, 2026, to discuss preclinical data for ERNA-101.
Read more →ERNAPhases
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Ernexa Therapeutics announced remarkable preclinical results for its lead cell therapy candidate, ERNA-101, which demonstrated complete tumor elimination and 100% long-term survival in ovarian cancer models. The therapy, in combination with PD-1 blockade, showed significant efficacy by converting the tumor microenvironment from immunosuppressive to immune-activated. With plans to advance ERNA-101 towards human trials, Ernexa aims to address the challenges posed by ovarian cancer treatments traditionally hindered by a non-responsive immune environment. The company intends to explore additional indications for ERNA-101 in other solid tumors as well.
Read more →ERNAGeneral
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
Ernexa Therapeutics has announced a 1-for-25 reverse stock split effective May 4, 2026, to comply with Nasdaq's minimum bid price requirement. This move aims to enhance the company's financial standing and visibility among investors. The split will adjust the number of shares outstanding while maintaining the rights of existing shares. The company is focused on advancing its clinical programs and strengthening its market position.
Read more →ERNAPhases
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Ernexa Therapeutics is advancing its lead product candidate, ERNA-101, toward first-in-human clinical trials anticipated to begin in Q4 2026. The company has demonstrated promising preclinical data showcasing its potential in treating platinum-resistant ovarian cancer. Key regulatory milestones, including an IND submission expected in Q3 2026, are set to support the company's transition from preclinical to clinical stages. Ernexa plans to leverage recent financing to fulfill critical upcoming milestones, positioning itself for significant value creation in the near term.
Read more →ERNAConferences/Events
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Ernexa Therapeutics will participate in the Virtual Investor Closing Bell Series on February 25, 2026. CEO Sanjeev Luther will present a corporate overview and engage with investors through a Q&A session. The event aims to enhance transparency and provide insights into Ernexa's innovative cell therapies for cancer and autoimmune diseases.
Read more →ERNAGeneral
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
Ernexa Therapeutics has announced the pricing of a public offering of 21 million shares at $0.50 each, expected to raise $10.5 million. The offering includes warrants with an exercise price of $0.68. Proceeds will be used for development programs and corporate purposes. The closing is anticipated around February 10, 2026, pending customary conditions.
Read more →ERNAFDA Updates
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
Ernexa Therapeutics recently participated in a Virtual Investor segment discussing its successful Pre-IND meeting with the FDA. The meeting confirmed regulatory alignment for its lead cell therapy, ERNA-101, aimed at treating ovarian cancer. The company is on track to submit an Investigational New Drug application and initiate clinical trials in the second half of 2026.
Read more →ERNAGeneral
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
Ernexa Therapeutics has been selected as one of ten global companies for the Japan Entry Acceleration Program (JEAP), a competitive initiative by JETRO. This selection underscores Ernexa's innovative cell therapy platform aimed at treating advanced cancer and autoimmune diseases. The program will provide mentoring and market-entry guidance, enhancing Ernexa's potential in the Japanese market. The company aims to advance its lead therapies, ERNA-101 and ERNA-201, through this initiative.
Read more →ERNAFDA Updates
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
Ernexa Therapeutics has announced a successful Pre-IND meeting with the FDA, indicating strong alignment for initiating their first-in-human trials for ovarian cancer in 2026. The company is currently accelerating operational activities, including tech transfer, to enhance clinical manufacturing readiness. Their lead product, ERNA-101, utilizes engineered induced mesenchymal stem cells for targeted therapy against ovarian cancer. This development reflects significant progress in delivering innovative cell therapies for serious diseases.
Read more →ERNAPhases
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
Ernexa Therapeutics presented new preclinical data on its cell therapy candidate ERNA-101 at the ASH Annual Meeting, showcasing the ability to reprogram tumor microenvironments to support immune activity. The findings highlight the potential of iPSC-derived mesenchymal stem cells to activate immune responses against cancers, including ovarian cancer. IL-7 and IL-15-secreting iMSCs demonstrated impressive immune cell infiltration and prolonged patient survival in animal models. The company is aiming to advance ERNA-101 into human clinical trials, indicating significant progress in their research efforts.
Read more →ERNAConferences/Events
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
Ernexa Therapeutics will present data from its cell therapy platform at the 67th American Society of Hematology Annual Meeting in December 2025. This presentation marks a significant milestone for the company, demonstrating the potential of their iMSC technology in cancer treatment. The lead therapy, ERNA-101, aims to enhance immune responses against tumors, particularly in ovarian cancer. The chosen presentation underlines the innovative approach Ernexa is taking in addressing hard-to-treat conditions.
Read more →ERNAGeneral
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
Ernexa Therapeutics has appointed Dr. Ira S. Winer to its Scientific and Medical Advisory Board, enhancing its capabilities in developing cell therapies for advanced cancer and autoimmune diseases. Dr. Winer's expertise in gynecologic oncology and translational science will support the advancement of Ernexa's iMSC platform and its lead program, ERNA-101, towards first-in-human trials. His strategic guidance is expected to help translate innovation into meaningful clinical outcomes.
Read more →ERNAConferences/Events
Ernexa Therapeutics to Present at Oxford Global’s Cell 2025
Ernexa Therapeutics will present at Cell 2025 in London on November 11-12, 2025. CEO Sanjeev Luther will discuss strategies for preparing cell therapies for clinical use and the challenges in navigating development. The event aims to foster collaboration among industry leaders in bioprocessing and advanced therapies, highlighting the role of AI in innovation.
Read more →ERNAGeneral
Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials
Ernexa Therapeutics reported a 44% reduction in operating loss year-over-year, reflecting strong operational execution. The company is advancing its lead program, ERNA-101, toward a Phase 1 study for platinum-resistant ovarian cancer expected in H2 2026. A partnership with Cellipont Bioservices is set to enhance the development of its innovative cell therapies.
Read more →ERNAGeneral
Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform
Ernexa Therapeutics has announced a strategic partnership with Cellipont Bioservices to advance its lead cell therapy, ERNA-101, for ovarian cancer. During a recent Virtual Investor segment, CEO Sanjeev Luther highlighted the collaboration's focus on Engineering, Differentiation, and Production activities. This partnership aims to facilitate clinical manufacturing and trials for ERNA-101, which utilizes innovative iPSC technology.
Read more →ERNAConferences/Events
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
Ernexa Therapeutics will present at the Cell & Gene Meeting on the Mesa on October 7. The presentation will focus on their progress in developing scalable iMSC therapies for cancer and autoimmune diseases. The company aims to highlight its lead therapy, ERNA-101, which targets ovarian cancer, and its approach to providing off-the-shelf treatments. The conference is a key event for advancing cell and gene therapies.
Read more →ERNAConferences/Events
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
Ernexa Therapeutics announced that its President and CEO, Sanjeev Luther, will present at the 5th Annual iPSC Drug Development Summit on October 1 in Boston. The company is advancing innovative cell therapies, including ERNA-101 for ovarian cancer and ERNA-201 for autoimmune diseases. Luther emphasized the potential of their synthetic iMSC approach to transform cell therapy.
Read more →ERNAConferences/Events
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
Ernexa Therapeutics announced that it will present preclinical data on its lead program, ERNA-101, at the AACR Special Conference in Cancer Research. The oral presentation will focus on how gene-modified iPS-derived MSCs can restore immune activity in high-grade serous ovarian cancer. This research highlights the potential of ERNA-101 to offer new therapeutic avenues in treating difficult tumors.
Read more →ERNAGeneral
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
Ernexa Therapeutics reported significant operational improvements for the first half of 2025, highlighted by a 51% reduction in operating expenses. The company is advancing its lead cell therapy product, ERNA-101, for ovarian cancer and continues to develop ERNA-201 for autoimmune diseases. These advancements are part of Ernexa's strategy to provide scalable, off-the-shelf cell therapies.
Read more →ERNAConferences/Events
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
Ernexa Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The presentation will cover the company's business, recent milestones, and its proprietary induced mesenchymal stem cell platform. Ernexa is focusing on two lead programs: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune diseases.
Read more →ERNAGeneral
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
Ernexa Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirements, allowing its stock to continue trading. The company is focused on advancing its innovative cell therapies, with plans to initiate its first clinical trial in early 2026. Their lead product, ERNA-101, aims to treat ovarian cancer, while ERNA-102 targets autoimmune diseases.
Read more →ERNAGeneral
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
Ernexa Therapeutics has expanded its Scientific Advisory Board to include a combined Scientific and Medical Advisory Board, marking a significant step towards clinical trials for ovarian cancer and autoimmune diseases. The new board members, Dr. Amir Jazaeri and Dr. Anna Jonsson, bring extensive expertise to guide the company's clinical strategies. This move follows Ernexa's strengthened financial position, aimed at accelerating its lead programs.
Read more →ERNAGeneral
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
Ernexa Therapeutics announced the successful completion of a second closing under a securities purchase agreement, raising approximately $6 million. The funds will be used for general working capital and to advance the company’s pipeline of cell therapies targeting advanced cancer and autoimmune diseases. The approval for the closing was obtained during the company’s Annual Meeting of Stockholders. Ernexa's lead product, ERNA-101, aims to activate the immune system to combat cancer cells, specifically ovarian cancer.
Read more →ERNAGeneral
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
Ernexa Therapeutics announced a 1-for-15 reverse stock split effective June 12, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement. This decision was approved by stockholders and is seen as part of the company's efforts to strengthen its financial position. Following the split, existing shareholders will find their shares automatically reclassified, although no fractional shares will be issued. The company is focused on advancing its clinical programs, including cell therapies for advanced cancer and autoimmune diseases.
Read more →ERNAConferences/Events
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
Ernexa Therapeutics announced new data to be presented at the ASCO Annual Meeting 2025, showcasing its innovative iMSC-based immunotherapy platform. The study, conducted in a mouse model of ovarian cancer, demonstrated significant tumor burden reduction and prolonged survival through the secretion of cytokines IL-7 and IL-15 by the engineered iMSCs. This approach aims to convert immunologically 'cold' tumors into 'hot' ones, potentially offering new treatment avenues for cancer patients. The presentation is scheduled for June 2, 2025, in Chicago, highlighting the company's commitment to advancing their cell therapy products.
Read more →ERNAGeneral
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
Ernexa Therapeutics has announced the launch of ErnexaTX2, a new subsidiary in Texas to support the development of its lead program, ERNA-101, aimed at treating ovarian cancer. This initiative is part of the company's strategy to streamline operations for anticipated clinical activities starting in 2026. The subsidiary will bolster collaboration with MD Anderson Cancer Center and enhance the company's capacity for clinical manufacturing and regulatory compliance. ERNA-101 is currently on track for IND-enabling studies in 2025, paving the way for future human trials.
Read more →ERNAConferences/Events
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
Ernexa Therapeutics presented new data at the AACR Annual Meeting 2025, highlighting the potential of their engineered induced mesenchymal stem cells (iMSCs) for treating ovarian cancer. The study demonstrated that these iMSCs can significantly slow tumor growth and enhance immune response by releasing immune-boosting cytokines. If successful, this treatment could provide a more effective and accessible option for patients who don't respond well to existing therapies. Ernexa's lead product, ERNA-101, is designed specifically for this purpose, showing promise in preclinical trials.
Read more →ERNAConferences/Events
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
Ernexa Therapeutics announced that new data on its lead cell therapy product, ERNA-101, will be presented at the AACR Annual Meeting 2025. The study focuses on its technology designed to directly treat ovarian tumors. Led by experts from MD Anderson Cancer Center, the research aims to optimize immune responses against difficult cancers. The company is positioning ERNA-101 as a significant innovation in cancer therapy, addressing a critical need for patients with limited options.
Read more →ERNAGeneral
Ernexa Therapeutics Closes New Funding Round
Ernexa Therapeutics has successfully closed a new funding round, raising approximately $7.25 million through a private placement of about 69.3 million shares. The funding will support the company's ongoing efforts in developing innovative cell therapies targeting ovarian cancer and autoimmune diseases. This follows a prior investment round in 2024, indicating strong investor confidence in Ernexa's strategic direction, particularly after its recent rebranding. The first closing of the funding occurred on April 2, 2025, with a second closure expected after obtaining necessary stockholder approval.
Read more →ERNAGeneral
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
Eterna Therapeutics Inc. has announced a $9.2 million financing deal involving senior convertible promissory notes and warrants. The company expects to close the initial transaction that will provide approximately $7.8 million in proceeds shortly. This financing is a strategic move to bolster its operations in mRNA cell engineering and other related technologies, though it also raises potential concerns regarding shareholder dilution and the inherent risks of developing innovative biopharma products.
Read more →ERNAConferences/Events
Eterna TherapeuticsInvestor Presentation August 2023 1 Eterna Therapeutics Inc. This presentation (this "Presentation") and any oral statements made in connection with this Presentation are for informational purposes onl
Eterna Therapeutics recently held an investor presentation detailing its advancements in mRNA cell engineering and gene editing technologies. The company highlighted its efforts to develop novel therapies for blood cancers, solid tumors, and other conditions utilizing its proprietary platforms. Eterna also emphasized its strong intellectual property position and the potential for substantial market opportunities through collaborations and partnerships. However, the presentation included cautionary notes about the inherent uncertainties in the biotechnology sector.
Read more →ERNAGeneral
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights - Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited indu
Eterna Therapeutics has reported its financial results for Q4 and the full year 2022, highlighting a net loss of $24.6 million. Significant developments include a license agreement with Lineage Cell Therapeutics, aimed at creating gene-edited therapies, and a new sublease for expanding its operations in Cambridge. The company also announced the appointment of Matt Angel, Ph.D. as its new CEO. Despite these advancements, the report revealed substantial R&D and administrative expenditures.
Read more →ERNAConferences/Events
Eterna TherapeuticsCompany Overview November 2022 1 Eterna Therapeutics Inc. Legal notices This presentation (this "Presentation") and any oral statements made in connection with this Presentation are for informational p
Eterna TherapeuticsCompany Overview November 2022 1 Eterna Therapeutics
Legal notices This presentation (this "Presentation") and any oral statements
made in connection with this Presentation are for informational purposes only and do not constitute an offer to sell, a solicita
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency SAN DIEGO, JUNE 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn" or the "
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
SAN DIEGO, JUNE 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical
company focused on developi
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Mee
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management:
Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President,
Andrew Jackson Appointed Chief Financial Officer
Postpones 2022 Annual Meeting
SAN DIEGO, MAY 31, 2022 (GLOBE NEWSWIRE) -- Brookly
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q SAN DIEGO, MAY 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) ("
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form
SAN DIEGO, MAY 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn"), a biopharmaceutical company focused on
exploring the
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results SAN DIEGO, APRIL 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn"), a biopharmaceutical com
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, APRIL 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role
that cytokine, gene edi
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement New York
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement
New York, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) ("Brooklyn"), a biopharmaceutical company focused on
exploring the role that cytokine, and gene editing/ce
Read more →ERNAConferences/Events
mRNA Engineered Cell & Genetic Medicines November 2021 A platform company in cell, gene-editing & cytokine therapies Disclaimer This presentation is intended to provide summary information about the business of Brooklyn
mRNA Engineered Cell & Genetic Medicines November 2021 A platform company in cell, gene-editing
& cytokine therapies
Disclaimer This presentation is intended to provide summary information about the business of Brooklyn
ImmunoTherapeutics, Inc. ("BTX"). The information in this
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq Ticker Symbol to Remain "BTX"
Brooklyn ImmunoTherapeutics to
Move Stock Exchange Listing to Nasdaq
Ticker Symbol to Remain "BTX"
NEW YORK, October 14, 2021 - Brooklyn
ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gen
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021
September 21, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/c
Read more →ERNAGeneral
Dear Brooklyn Immunotherapeutics, Inc. ("Brooklyn") Shareholder: We are pleased to announce that Computershare Trust Company, N.A. ("Computershare") has been appointed as the stock transfer agent and registrar for Brookl
www.computershare.com
1-800-736-3001 (U.S.)
1-781-575-3100 (non-U.S.)
web.queries@computershare.com
Louisville KY 40233-5000
462 South 4th Street Louisville KY 40233-5000
140 58th Street, Building A, Suite 2100, Brooklyn, New York 11220 | tel: (212) 582-1199 | brooklynitx.c
Read more →ERNAConferences/Events
September 2021 mRNA Engineered Cell & Cytokine Medicines A platform company in cell, gene-editing & cytokine therapies Disclaimer This presentation is intended to provide summary information about the business of Brookly
September 2021 mRNA Engineered Cell & Cytokine Medicines A platform company in cell, gene-editing
& cytokine therapies
Disclaimer This presentation is intended to provide summary information about the business of Brooklyn
ImmunoTherapeutics, Inc. ("BTX"). The information in th
Read more →ERNAConferences/Events
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum Brooklyn, NY
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
Brooklyn, NY - August 20, 2021 - Brooklyn
ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokin
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results
Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results
August 12, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that gene editing/cell and cytokine therapy can have
in t
Read more →ERNAConferences/Events
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy Company to hold Conference Call Toda
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy
Company to hold Conference Call Today, July 19, 2021, at 4:15PM ET to Discuss the Transaction
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer Brooklyn, NY
Brooklyn ImmunoTherapeutics Welcomes
Jay Sial as Chief Administrative Officer
Brooklyn, NY - July 13, 2021 - Brooklyn ImmunoTherapeutics,
Inc. (NYSE American: BTX) ("Brooklyn" or "the Company"), a biopharmaceutical company focused on exploring the role that cytokine and gene e
Read more →ERNAGeneral
Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D'Amour as Chief Scientific Officer Brooklyn, NY
Brooklyn ImmunoTherapeutics Welcomes
Dr. Kevin A. D'Amour as Chief Scientific Officer
Brooklyn, NY - June 8, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE
American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cel
Read more →ERNAGeneral
Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc. Brooklyn, NY
Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.
Brooklyn, NY - April 6, 2021 - Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn" or "the Company"), a biopharmaceutical company focused on exploring the role that
Read more →ERNAGeneral
NTN Buzztime Announces Proposed Reverse Stock Split Ratio and Anticipated Closing of Merger Carlsbad, CA
Buzztime Announces Proposed Reverse Stock Split Ratio
and Anticipated Closing of Merger
CA, March 23, 2021 /PRNewswire/ - NTN Buzztime, Inc. (NYSE American: NTN) today announced
that it plans to effect a one for two reverse stock split of its outstanding shares of common stock
Read more →ERNAFDA Updates
NTN Buzztime Announces Approval of Merger with Brooklyn Immunotherapeutics by Stockholders at Special Meeting Carlsbad, CA
Buzztime Announces Approval of Merger with Brooklyn Immunotherapeutics by Stockholders at Special Meeting
CA, March 15, 2021 / PRNewswire/ - NTN Buzztime, Inc. (NYSE American: NTN) today announced that its stockholders
have approved the proposed merger between NTN and Brooklyn
Read more →ERNAGeneral
Independent Advisory Firm ISS Recommends NTN Stockholders Vote FOR Proposed Merger and Asset Sale and ALL Related Proposals
Advisory Firm ISS Recommends NTN Stockholders Vote FOR Proposed Merger and Asset Sale and ALL Related Proposals
Calif., March 8, 2021 /PRNewswire/ - NTN Buzztime, Inc. (NYSE American: NTN) today announced that leading independent proxy
advisory firm Institutional Shareholder Se
Read more →ERNAPhases
Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer Brooklyn, NY
ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in
Negative Breast Cancer
NY - February 9, 2021 - Brooklyn ImmunoTherapeutics LLC ("Brooklyn"), a biopharmaceutical company
focused on exploring the role that c
Read more →ERNAGeneral
NTN Buzztime Announces Date of Special Meeting of Stockholders to Vote on Proposed Merger and Asset Sale
Buzztime Announces Date of Special Meeting of Stockholders
Vote on Proposed Merger and Asset Sale
Calif., Feb. 3, 2021 /PRNewswire/ - NTN Buzztime, Inc. (NYSE American: NTN), today announced that its registration
statement on Form S-4 relating to the proposed merger involving
Read more →ERNAGeneral
NTN Buzztime, Inc. Receives Noncompliance Notice from NYSE American
Buzztime, Inc. Receives Noncompliance Notice from NYSE American
Calif., January 15, 2021, - NTN Buzztime, Inc. (NYSE American: NTN), announced it received a letter from the NYSE Regulation
stating that it is not in compliance with NYSE American LLC continued listing standards.
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Third Quarter 2020 Results
Buzztime, Inc. Reports Third Quarter 2020 Results
Calif., November 13, 2020 - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the third quarter
ended September 30, 2020.
is working diligently toward closing two transformative transactions," said Allen W
Read more →ERNAGeneral
NTN Buzztime Enters Asset Purchase Agreement to Sell Entertainment and Advertising Assets The asset sale complements Buzztime's previously announced proposed reverse merger Carlsbad, CA, September XX, 2020 -NTN Buzztime,
Buzztime Enters Asset Purchase Agreement
Sell Entertainment and Advertising Assets
CA, September XX, 2020 -NTN Buzztime, Inc. (NYSE American: NTN) signed a definitive asset purchase agreement to sell its
social entertainment, customer engagement, and advertising technology ass
Read more →ERNAGeneral
NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement -Proposed merger will create a public company focused on the clinical development program of a cytokine-based product for the
Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC
into Definitive Merger Agreement
merger will create a public company focused on the clinical development
of a cytokine-based product for the treatment of cancer
company expected to trade on the NYSE American under a new ticke
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Second Quarter 2020 Results
Buzztime, Inc. Reports Second Quarter 2020 Results
Calif., August 7, 2020 - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the second quarter ended
negative impact of the COVID-19 pandemic on our customers was abrupt and substantial, and it had a ripple
Read more →ERNAGeneral
NYSE Regulation Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by September 2021
Regulation Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by September 2021
Calif., June 15, 2020 - NTN Buzztime, Inc. (NYSE American: NTN), announced it received a letter from NYSE Regulation, Inc.
on June 11, 2020, stating it accepted the company's plan to regain co
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports First Quarter 2020 Results
Buzztime, Inc. Reports First Quarter 2020 Results
Calif., May 19, 2020 - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the first quarter ended March
Wolff, CEO, said, "We started 2020 focused on growing our business in an efficient manner. Shifting the
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Fourth Quarter and Full Year 2019 Results
NTN Buzztime, Inc. Reports Fourth Quarter
and Full Year 2019 Results
CARLSBAD, Calif., March 17, 2020, - NTN
Buzztime, Inc. (NYSE American: NTN), reported financial results for the fourth quarter and year ended December 31, 2019.
Allen Wolff, CEO, said, "During the fourth
qu
Read more →ERNAGeneral
NTN Buzztime Signs Definitive Agreement to Sell Stump! Trivia for $1.4 Million - Continues Emphasis on Digital and Hardware Entertainment Strategy and Divests the Ancillary Hosted Events
Buzztime Signs Definitive Agreement to Sell Stump! Trivia for $1.4 Million
Continues Emphasis on Digital and Hardware Entertainment Strategy and Divests the Ancillary Hosted Events -
Calif., January 14, 2020, - NTN Buzztime, Inc. (NYSE American: NTN), signed a definitive agreem
Read more →ERNAGeneral
NTN Buzztime Appoints Game Development Expert Michael Gottlieb to the Board - Jeff Berg and Steve Mitgang Retire from the Board
Buzztime Appoints Game Development Expert Michael Gottlieb to the Board
Jeff Berg and Steve Mitgang Retire from the Board -
Calif., November 26, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), appointed game development expert Michael Gottlieb
as an independent, non-executive
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Third Quarter 2019 Results - Grew Cash Flow from Operations to $1.8 Million YTD 2019, Up from $528,000 YTD 2018 - - Signed Repeat Customer for $3 Million Hardware Deal - - Secured Hardware Part
Buzztime, Inc. Reports Third Quarter 2019 Results
Grew Cash Flow from Operations to $1.8 Million YTD 2019, Up from $528,000 YTD 2018 -
Signed Repeat Customer for $3 Million Hardware Deal -
Secured Hardware Partnership to Enable Digital Marketing and Loyalty Platform-
Calif.,
Read more →ERNAGeneral
NTN Announces CEO Transition - Ram Krishnan to Depart; CFO Allen Wolff to Act as Interim CEO
Announces CEO Transition
Ram Krishnan to Depart; CFO Allen Wolff to Act as Interim CEO -
Calif., September 17, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), announced CEO Ram Krishnan will resign as CEO of
the company effective September 17, 2019 and serve as an advisor thr
Read more →ERNAGeneral
NTN Announces Board Transition
Announces Board Transition
Calif., September 3, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), changed the composition of its board of directors
effective August 30, 2019. Gregg Thomas, a current director, was named chair, replacing Jeff Berg, who will remain on the board.
S
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Second Quarter 2019 Results - Signs Repeat Customer for $3 Million Deal - - Increases Footprint with Mobile App
Buzztime, Inc. Reports Second Quarter 2019 Results
Signs Repeat Customer for $3 Million Deal -
Increases Footprint with Mobile App -
Calif., August 9, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the second quarter ended
the second quarter,
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports First Quarter 2019 Results Launches Buzztime Entertainment App in Open Beta Expanding Target Market
Buzztime, Inc. Reports First Quarter 2019 Results
Buzztime Entertainment App in Open Beta Expanding Target Market
Calif., May 13, 2019, - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the first quarter ended
Buzztime continues to evolve, we remain com
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Fourth Quarter and Full Year 2018 Results - Grew Q4 2018 Revenue 12% to $5.9 Million - - Reported Q4 2018 GAAP Net Income Attributable to Common Shareholders of $44,000 - - Posted $732,000 in Q
Buzztime, Inc. Reports Fourth Quarter and Full Year 2018 Results
Grew Q4 2018 Revenue 12% to $5.9 Million -
Reported Q4 2018 GAAP Net Income Attributable to Common Shareholders of $44,000 -
Posted $732,000 in Q4 2018 EBITDA, Marking Eleventh Consecutive Quarter Positive -
Cal
Read more →ERNAGeneral
NTN Buzztime Exploring Strategic Alternatives
Buzztime Exploring Strategic Alternatives
Calif., December 7, 2018 - NTN Buzztime, Inc. (NYSE American: NTN) today announced that its board of directors is exploring
and evaluating strategic alternatives focused on maximizing shareholder value, including, among other things, a
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Third Quarter 2018 Results - Grew Revenue 15.5% to $6.0 Million, Up from $5.2 Million Q3 2017 - - Recorded GAAP Net Income of $222,000 - - Posted $1.1 Million in EBITDA, Marking Tenth Consecuti
Buzztime, Inc. Reports Third Quarter 2018 Results
Grew Revenue 15.5% to $6.0 Million, Up from $5.2 Million Q3 2017 -
Recorded GAAP Net Income of $222,000 -
Posted $1.1 Million in EBITDA, Marking Tenth Consecutive Quarter Positive -
Calif., November 7, 2018, - NTN Buzztime, In
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Second Quarter 2018 Results - Grew Revenue to $5.7 Million, Up from $5.5 Million Q2 2017 - - Improved GAAP Net Loss to $124,000 and Achieved Ninth Consecutive Quarter of Positive EBITDA
Buzztime, Inc. Reports Second Quarter 2018 Results
Grew Revenue to $5.7 Million, Up from $5.5 Million Q2 2017 -
Improved GAAP Net Loss to $124,000 and
Achieved Ninth Consecutive Quarter of Positive EBITDA -
Calif., August 2, 2018, - NTN Buzztime, Inc. (NYSE American: NTN), re
Read more →ERNAGeneral
NTN Buzztime Announces $1.6 Million Registered Direct Offering of Common Stock
Buzztime Announces $1.6 Million Registered Direct Offering of Common Stock
Calif., June 27, 2018 - NTN Buzztime, Inc. (NYSE MKT: NTN) today announced that it has entered into a subscription agreement
with certain investors relating to a registered direct offering in which the c
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports First Quarter 2018 Results - Grew Revenue to $5.8 Million, Up 10% from Q1 2017 - - Improved Gross Margins to 66%, Up from 65% in Q1 2017 - - Achieved Eighth Consecutive Quarter of Positive EBIT
Buzztime, Inc. Reports First Quarter 2018 Results
Grew Revenue to $5.8 Million, Up 10% from Q1 2017 -
Improved Gross Margins to 66%, Up from 65% in Q1 2017 -
Achieved Eighth Consecutive Quarter of Positive EBITDA -
Calif., May 9, 2018, - NTN Buzztime, Inc. (NYSE American: NTN
Read more →ERNAGeneral
NYSE Regulation Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by March 2019
Regulation Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by March 2019
Calif., April 30, 2018 - NTN Buzztime, Inc. (NYSE American: NTN), leader in interactive entertainment and innovative dining
technology to bars and restaurants in North America, announced it receiv
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Fourth Quarter and Full Year 2017 Results - Annual Gross Margins of 68%, up from 65% in 2016 - - Seventh consecutive quarter of positive EBITDA
Buzztime, Inc. Reports Fourth Quarter and Full Year 2017 Results
Annual Gross Margins of 68%, up from 65% in 2016 -
Seventh consecutive quarter of positive EBITDA -
Calif., March 6, 2018, 2017 - NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the fourth
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Third Quarter 2017 Results - Gross Margin reaches 70%
NTN Buzztime, Inc. Reports Third Quarter
- Gross Margin reaches
CARLSBAD, Calif., November 7, 2017 -
NTN Buzztime, Inc. (NYSE American: NTN), reported financial results for the third quarter ended September 30, 2017.
"During the third quarter, we continued
executing consiste
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Second Quarter 2017 Results
Buzztime, Inc. Reports Second Quarter 2017 Results
Calif., August 2, 2017 - NTN Buzztime, Inc. (NYSE American: NTN) reported financial results for the second quarter
ended June 30, 2017.
Recorded GAAP net loss of $164,000 in Q2 2017, a $686,000 improvement compared to Q2 2016
Read more →ERNAGeneral
NTN Buzztime Appoints Two New Independent Members to the Board of Directors
Buzztime Appoints Two New Independent Members
the Board of Directors
Calif., July 10, 2017- NTN Buzztime, Inc. (NYSE MKT: NTN) appointed independent directors Gregg Thomas, 56, and Richard
Simtob, 47, to its board of directors effective July 7, 2017. They will replace Mary Bet
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports First Quarter 2017 Results -Records GAAP Net loss of $90,000, a $1 million improvement compared to 2016 - -Reports positive EBITDA for fourth consecutive quarter - Completes financing initiativ
Buzztime, Inc. Reports First Quarter 2017 Results
GAAP Net loss of $90,000, a $1 million improvement compared to 2016 -
positive EBITDA for fourth consecutive quarter
Completes financing initiatives, anticipates regaining NYSE MKT listing compliance -
Launches Spaceteam multi
Read more →ERNAGeneral
NTN Buzztime Announces Registered Direct Offering of Common Stock
Buzztime Announces Registered Direct Offering of Common Stock
Calif., April 25, 2017 - NTN Buzztime, Inc. (NYSE MKT: NTN) today announced that before the market opened today it entered into
a subscription agreement with certain investors relating to a registered direct offering
Read more →ERNAGeneral
NTN Buzztime, Inc. Expands Partnership with Buffalo Wild Wings and Reports Fourth Quarter and Year-end 2016 Results - Improves 2016 Net Loss by $4.3 million compared to 2015 - - Buzztime Selected to Deliver Order and Pay
NTN Buzztime, Inc. Expands Partnership with
Buffalo Wild Wings and
Reports Fourth Quarter and Year-end 2016
- Improves 2016 Net Loss by $4.3
million compared to 2015 -
- Buzztime Selected to Deliver Order
and Pay with EMV Functionality to Buffalo Wild Wings -
CARLSBAD, Cal
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Third Quarter 2016 Results - Receives $2.7 Million in Net Proceeds Subsequent to Quarter End - - Improves Net Loss to $573,000, Compared to Net Loss of $1.3 Million in the Third Quarter 2015
NTN Buzztime, Inc. Reports Third Quarter
- Receives $2.7 Million
in Net Proceeds Subsequent to Quarter End -
to $573,000, Compared to Net Loss of $1.3 Million in the Third Quarter 2015 -
CARLSBAD, Calif., November 8, 2016 -
NTN Buzztime, Inc. (NYSE MKT: NTN), reported financ
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Second-Quarter 2016 Results - Improves Net Loss by $1.8 million to $850,000, Compared to Second Quarter 2015 - - Generates over $500,000 in Quarterly Cash from Operations
Reports Second-Quarter 2016 Results
Net Loss by $1.8 million to $850,000, Compared to Second Quarter 2015 -
over $500,000 in Quarterly Cash from Operations -
CARLSBAD, Calif., August 3, 2016 - NTN
Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the second quart
Read more →ERNAGeneral
Buzztime Announces Anticipated Effective Date of Reverse/Forward Stock Split Carlsbad, CA
Announces Anticipated Effective Date of Reverse/Forward Stock Split
CA - June 7, 2016 - NTN Buzztime, Inc. (NYSE MKT:NTN), a leader in interactive entertainment and innovative
dining technology, today announced the expected effective date of its 1-for-100 reverse stock split (t
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports First-Quarter 2016 Results - Launches Order and Payment at Buffalo Wild Wings - - Delivers Better than Expected First Quarter with Positive Adjusted EBITDA
Reports First-Quarter 2016 Results
Order and Payment at Buffalo Wild Wings -
Better than Expected First Quarter with Positive Adjusted EBITDA -
CARLSBAD, Calif., May 6, 2016 - NTN
Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the first quarter ended March 31,
Read more →ERNAGeneral
NTN Buzztime, Inc. Amends Credit Agreement, Increasing Access to Short-term Capital
Buzztime, Inc. Amends Credit Agreement, Increasing Access to Short-term Capital
Calif., March 11, 2016 - NTN Buzztime, Inc. (NYSE MKT: NTN), a leader in interactive entertainment and innovative dining
technology, amended its credit agreement with East West Bank to increase the
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Fourth-Quarter 2015 Results - Achieves Adjusted EBITDA Positive for Fourth Quarter 2015
Buzztime, Inc. Reports Fourth-Quarter 2015 Results
Achieves Adjusted EBITDA Positive for Fourth Quarter 2015 -
Calif., March 11, 2016 - NTN Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the fourth quarter and year
ended December 31, 2015.
was a pivotal year f
Read more →ERNAConferences/Events
PRESENTATION Safe Harbor This presentation contains forward - looking statements which reflect management's current views of future events and operations, including but not limited to statements about our growth plans, p
Safe Harbor This presentation contains forward - looking statements which reflect management's current views of future events and operations, including but not limited to statements about our growth plans, product and platform development, new revenue, customer development, impro
Read more →ERNAGeneral
NYSE Accepts Plan for NTN Buzztime, Inc. to Regain Compliance by May 2017
Plan for NTN Buzztime, Inc. to Regain Compliance by May 2017
CARLSBAD, Calif., February 2, 2016 -
NTN Buzztime, Inc. (NYSE MKT: NTN), leader in interactive entertainment and innovative dining technology to bars and restaurants
in North America, announced it received a letter f
Read more →ERNAGeneral
NTN Buzztime, Inc. Preannounces Fourth-Quarter 2015 Metrics -Increased site count for the third quarter in a row- -Expects to be Adjusted EBITDA Positive for Fourth Quarter 2015
Inc. Preannounces Fourth-Quarter 2015 Metrics
site count for the third quarter in a row-
to be Adjusted EBITDA Positive for Fourth Quarter 2015-
CARLSBAD, Calif., January 28, 2016 -
NTN Buzztime, Inc. (NYSE MKT: NTN), today announced preliminary Adjusted EBITDA for the fourth
Read more →ERNAConferences/Events
Safe Harbor This presentation contains forward - looking statements which reflect management's current views of future events and operations, including but not limited to statements about our growth plans, product and pl
Safe Harbor This presentation contains forward - looking statements which reflect management's current views of future events and operations, including but not limited to statements about our growth plans, product and platform development, new revenue, customer development, impro
Read more →ERNAGeneral
NTN Buzztime, Inc. Receives Noncompliance Notice from
NTN Buzztime, Inc. Receives Noncompliance
Notice from NYSE MKT
CARLSBAD, Calif., November 16, 2015 -
NTN Buzztime, Inc. (NYSE MKT: NTN), leader in interactive entertainment and innovative dining technology to bars and restaurants
in North America, announced it received of a l
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Third-Quarter 2015 Results -Increased site count for the second quarter in a row- -Signed two master service agreements with experience-focused chains- -Deployed payment capabilities with estab
NTN Buzztime, Inc. Reports Third-Quarter
-Increased site count
for the second quarter in a row-
-Signed two master service agreements with experience-focused chains-
capabilities with established partner venue-
CARLSBAD, Calif., November 5, 2015 -
NTN Buzztime, Inc. (NYSE M
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Second-Quarter 2015 Results - Grew revenue 8% sequentially
NTN Buzztime, Inc. Reports Second-Quarter
- Grew revenue 8% sequentially
CARLSBAD, Calif., August 6, 2015 - NTN
Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the second quarter ended June 30, 2015.
"Second quarter revenue grew 8% sequentially,
reflecting pos
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports First-Quarter 2015 Results - The BEOND Platform Reaches 43% of the Installed Base - - Aligns Business to Key Initiatives and Reduces Future Operating Expenses
NTN Buzztime, Inc. Reports First-Quarter
- The BEOND Platform Reaches
43% of the Installed Base -
- Aligns Business to Key Initiatives
and Reduces Future Operating Expenses -
CARLSBAD, Calif., May 7, 2015 - NTN Buzztime,
Inc. (NYSE MKT: NTN), reported financial results for
Read more →ERNAGeneral
NTN Buzztime, Inc. Secures New Credit Agreement - Increases financial flexibility and reduces interest obligation
NTN Buzztime, Inc. Secures New
- Increases financial flexibility
and reduces interest obligation -
CARLSBAD, Calif., April 16, 2015 - NTN
Buzztime, Inc. (NYSE MKT: NTN), a leading provider of in-venue social gaming and entertainment, announced the closing of a three-year
rev
Read more →ERNAGeneral
NTN Buzztime, Inc. Reports Fourth-Quarter and Full-Year 2014 Results - The BEOND Platform Reaches 1,106 Sites, 37% of the Installed Base at Q4 2014 Close
NTN Buzztime, Inc. Reports Fourth-Quarter
and Full-Year 2014 Results
- The BEOND Platform Reaches
1,106 Sites, 37% of the Installed Base at Q4 2014 Close -
CARLSBAD, Calif., March 26, 2015 -
NTN Buzztime, Inc. (NYSE MKT: NTN), reported financial results for the fourth-quarte
Read more →ERNAGeneral
NTN Buzztime Names Allen Wolff Chief Financial Officer
NTN Buzztime Names Allen Wolff Chief
CARLSBAD, Calif., December 19, 2014
- NTN Buzztime, Inc. (NYSE MKT: NTN) hired Allen Wolff, 42, as chief financial officer effective December 29, 2014.
Wolff, among other responsibilities, will assume the principal accounting duties and rep
Read more →ERNAGeneral
WE ENTERTAIN CONSUMERS IN WAYS THAT CREATE LONG TERM VALUE FOR MERCHANTS. WE PUT PLAY TO WORK. Ticker: NTN Exchange
WE ENTERTAIN CONSUMERS IN WAYS THAT CREATE LONG TERM VALUE FOR MERCHANTS. WE PUT PLAY TO WORK. Ticker: NTN Exchange: NYSE MKT March 11, 2014
This presentation includes statements that may constitute "forward - looking statements," including estimates of future business prospects
Read more →ERNAGeneral
PRESS RELEASE ntn_8kex99-1.htm
Chief Financial Officer
CCG Investor Relations
NTN Buzztime, Inc. Announces Fourth Quarter and Full Year 2012 Results
CARLSBAD, Calif., March 28, 2013 - NTN Buzztime, Inc. (NYSE MKT: NTN) today announced results for the fourth quarter and year ended December 31, 2012.
"In the
Read more →